One of the DEGs, developmentally regulated GTP-binding protein 2 (DRG2), was a particularly striking outlier, and was consistently downregulated in ATRX-mutant low grade glioma (Fig. 4B). This evidence concerns the gene DRG2 and central nervous system cancer.